Tessera Therapeutics

Tessera Therapeutics is a Flagship Pioneering biotechnology company pioneering Gene Writing, a novel genome engineering platform that uses mobile genetic elements to make permanent, programmable changes to the human genome. Unlike CRISPR-based editing, Gene Writing can make small and large alterations without double-strand DNA breaks. The company is advancing in vivo programs for rare diseases including alpha-1 antitrypsin deficiency and sickle cell disease, with Regeneron as a key development partner.